Calliditas Therapeutics to Present at Kidney Week
Calliditas Therapeutics, an Asahi Kasei company, is excited to announce its participation in the upcoming American Society of Nephrology Kidney Week. This premier event, which gathers kidney health professionals from around the world, provides a platform for sharing the latest advancements in kidney research and treatment.
Key Presentations and Data Reveal
At this year's Kidney Week, Calliditas will share new data from the Phase 3 NefIgArd study, focusing on the therapeutic potential of Nefecon, also known as TARPEYO. This medication is designed for patients diagnosed with primary immunoglobulin A nephropathy (IgAN) who are at risk of worsening kidney function.
Patients suffering from IgAN experience the deposition of harmful immune complexes within their kidneys, leading to inflammation and progressive renal damage. The new analyses will shed light on treatment responses and patient demographics in the PERFORM registry, which tracks real-world outcomes for IgAN patients treated with TARPEYO.
Highlighting Innovation in Kidney Health
One of the standout presentations will focus on a Phase 2a trial of setanaxib, a novel treatment being tested for Alport Syndrome, a genetic disorder that leads to kidney failure. This will be featured during a High-Impact Clinical Trials session, underlining Calliditas' commitment to addressing rare and complex kidney diseases.
Eight abstracts from Calliditas Theraputics have been accepted for presentation at the conference, including both oral and poster formats. This diverse range of presentations emphasizes the company's dedication to advancing the understanding and treatment of kidney diseases.
Details About the Conference Schedule
The conference will take place from November 6 to 9, with key presentations scheduled throughout the event. One pivotal session involves a detailed look at the long-term efficacy of Nefecon over two years, demonstrating how this treatment can provide sustained benefits to patients.
Additionally, presentations will cover critical findings on real-world treatment patterns in the Veterans Health Administration, providing valuable insights into the management of IgAN in diverse patient populations.
As part of its commitment to education and collaboration, Calliditas encourages all conference attendees to engage in discussions about improving patient outcomes through innovative treatment strategies.
Calliditas' Commitment to Kidney Health
Calliditas Therapeutics is dedicated to developing and commercializing treatments for rare kidney diseases. With a focus on unmet medical needs, the company strives to provide solutions that enhance patient care and outcomes.
Frequently Asked Questions
What is the significance of Calliditas presenting at Kidney Week?
The presentation at Kidney Week allows Calliditas to share important findings and advancements in treatments for kidney diseases, fostering collaboration and innovation in the field.
What is Nefecon and its relevance to IgAN?
Nefecon is a delayed-release formulation of budesonide that targets IgAN and aims to reduce kidney function deterioration in patients at risk of disease progression.
What information will be shared about setanaxib?
Data on setanaxib's efficacy in treating Alport Syndrome will be revealed, highlighting its potential benefits for patients dealing with this rare genetic disorder.
How does Calliditas support patient education?
Calliditas is committed to educating healthcare providers and patients on the latest research and treatment options for kidney diseases to improve patient outcomes.
Where is Calliditas Therapeutics headquartered?
Calliditas Therapeutics is headquartered in Stockholm, Sweden, and focuses on developing treatments for rare diseases.
